Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors.

about

Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors.

Item

http://www.wikidata.org/entity/Q51515954

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Phase I and pharmacokinetic ev ...... atin in advanced solid tumors.

@en

Phase I and pharmacokinetic ev ...... atin in advanced solid tumors.

@nl

type

Item

label

Phase I and pharmacokinetic ev ...... atin in advanced solid tumors.

@en

Phase I and pharmacokinetic ev ...... atin in advanced solid tumors.

@nl

prefLabel

Phase I and pharmacokinetic ev ...... atin in advanced solid tumors.

@en

Phase I and pharmacokinetic ev ...... atin in advanced solid tumors.

@nl

P1476

Phase I and pharmacokinetic ev ...... atin in advanced solid tumors.

@en

P2093

Jogarao Gobbru

http://www.w3.org/2001/XMLSchema#string

Josephine Feliciano

http://www.w3.org/2001/XMLSchema#string

Martin J Edelman

http://www.w3.org/2001/XMLSchema#string

Miroslav Styblo

http://www.w3.org/2001/XMLSchema#string

Rena Lapidus

http://www.w3.org/2001/XMLSchema#string

P2860

Specific association of human telomerase activity with immortal cells and cancer

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

The RNA component of human telomerase

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

A survey of telomerase activity in human cancer

Telomerase catalytic subunit homologs from fission yeast and human

KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells.

Telomerase and cancer: time to move from a promising target to a clinical reality.

KML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model.

Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.

P2888

s00280-016-3148-x

P304

959-967

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-016-3148-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jan H Beumer

Tao Liu

P577

2016-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27620207

http://www.w3.org/2001/XMLSchema#string